|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 101 | 2019 | Neuromyelitis Optica in Flanders: an epidemiological study | Blomme, L.; MOONS, Lynn; Noels, S.; Laureys, G.; VAN WIJMEERSCH, Bart; Crols, R.; DE KLIPPEL, Nina; Van de Velde, K.; Willekens, B. | Journal Contribution | M |
| 102 | 2019 | Machine learning analysis of motor evoked potential time series to predict disability progression in multiple sclerosis | YPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; POPESCU, Veronica; HELLINGS, Niels; VAN WIJMEERSCH, Bart; PEETERS, Liesbet | Journal Contribution | M |
| 103 | 2019 | Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) | McCombe, P.; Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H-P; Havrdova, E. K.; Inshasi, J. S.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 104 | 2019 | No Association Between Lymphocyte Pharmacodynamics and Disability Following Alemtuzumab Treatment in patients With Relapsing-Remitting Multiple Sclerosis | Meuth, Sven G.; Brandes, David; Carraro, Matthew; Comi, Giancarlo; Mao-Draayer, Yang; Izquierdo, Guillermo; Kim, Ho Jin; Pardo, Gabriel; Sharrack, Basil; Tornatore, Carlo; VAN WIJMEERSCH, Bart; Ziemssen, Tjalf; Jacobs, Alan; Chung, Luke; Daizadeh, Nadia; Wiendl, Heinz | Journal Contribution | M |
| 105 | 2019 | Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study) | Montalban, X.; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M.; Lycke, J.; Massacesi, L.; Naismith, R. T.; Nakamura, K.; Pandey, K.; Schippling, S.; Vermersch, P.; Wiendl, H.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 106 | 2019 | IgD(-)CD27(-) double negative B cells of multiple sclerosis patients have a pro-inflammatory migratory phenotype and function | BECKERS, Lien; Diaz, G. Montes; Villar, L. M.; VAN WIJMEERSCH, Bart; SOMERS, Veerle; FRAUSSEN, Judith | Journal Contribution | M |
| 107 | 2019 | Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial | Cambron, Melissa; Mostert, Jop; D'Hooghe, Marie; Nagels, Guy; Willkens, Barbara; Debruyne, Jan; Algoed, Luc; Verhagen, Winn; Hupperts, Raymond; Heersema, Dorothea; De Keyser, Jacques; De Groot, Liesbeth; Foselle, Erwin; Guillaume, Daniel; Merckx, Henri; Vanopdenbosch, Ludo; Vokaer, Mathieu; DE KLIPPEL, Nina; Nuytten, Dirk; Van Remoortel, Ann; Symons, Anoek; D'haeseleer, Miguel; Bissay, Veronique; Van Merhaegen-Wieleman, Annick; Van Lint, Michel; Michiels, Veronique; Haentjens, Patrick; VAN WIJMEERSCH, Bart; Tillemans, Bart; Van Hecke, Wim; Hengstman, Gerald | Journal Contribution | A1 |
| 108 | 2019 | Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years | Vermersch, P.; Baker, M.; Bass, A. D.; Berkovich, R.; Comi, G.; Eichau, S.; Graves, D.; Hunter, S. F.; Ionete, C.; Limmroth, V.; Meuth, S. G.; Naismith, R. T.; Sharrack, B.; Subei, A.; Daizadeh, N.; Choudhry, Z.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 109 | 2019 | Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study) | Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H. -P.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 110 | 2019 | Deciphering morphology of Evoked Potentials | YPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; HELLINGS, Niels; Cambron, M.; Dive, D.; Laureys, G.; POPESCU, Veronica; VAN WIJMEERSCH, Bart; PEETERS, Liesbet | Journal Contribution | M |
| 111 | 2019 | Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression | DE BROUWER, Edward; PEETERS, Liesbet; BECKER, Thijs; Altintas, A.; Soysal, A.; VAN WIJMEERSCH, Bart; Boz, C.; Oreja-Guevara, C.; Gobbi, C.; Solaro, C.; Ramo, C.; Spitaleri, D. L.; Maimone, D.; Aguera-Morales, E.; Cartechini, E.; Butler, E.; Havrdova, E.; Patti, F.; Granella, F.; Grand'Maison, F.; Moore, F.; Verheul, F.; Luliano, G.; Butzkueven, H.; Lechner-Scott, J.; Kuhle, J.; Sanchez Menoyo, J. L.; Rojas, J. I.; Prevost, J.; Onofrj, M.; Rio, M. E.; Sa, M. J.; Saladino, M. L.; Slee, M.; Barnett, M.; Terzi, M.; Deri, N.; McCombe, P.; Sola, P.; Duquette, P.; Grammond, P.; Ampapa, R.; Alroughani, R.; Hupperts, R.; Turkoglu, R.; Gouider, R.; Fernandez Bolanos, R.; Bergamaschi, R.; Kalincik, T.; Moreau, Y. | Journal Contribution | M |
| 112 | 2019 | Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS | Kalincik, T.; Malpas, C. B.; ROOSEN, Inge; Patti, F.; Butzkueven, H.; Alroughani, R.; Izquierdo, G.; Eichau, S.; Onofrj, M.; Lugaresi, A.; Hupperts, R.; Lechner-Scott, J.; Sola, P.; Ferraro, D.; Grammond, P.; Csepany, T.; Grand'Maison, F.; Yamout, B.; Prat, A.; Girard, M.; Duquette, P.; VAN WIJMEERSCH, Bart; Granella, F.; Sa, M. J.; Bergamaschi, R.; Slee, M.; Boz, C.; Ozakbas, S.; Terzi, M.; Prevost, J.; Solaro, C.; Macdonell, R.; Cartechini, E.; Coles, A.; Havrdova, E. K.; Horakova, D. | Journal Contribution | M |
| 113 | 2019 | Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis | Kalincik, Tomas; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Grammond, Pierre; Onofrj, Marco; Lugaresi, Alessandra; Ozakbas, Serkan; Kappos, Ludwig; Kuhle, Jens; Terzi, Murat; Lechner-Scott, Jeannette; Boz, Cavit; Grand'Maison, Francois; Prevost, Julie; Sola, Patrizia; Ferraro, Diana; Granella, Franco; Trojano, Maria; Bergamaschi, Roberto; Pucci, Eugenio; Turkoglu, Recai; McCombe, Pamela A.; Van Pesch, Vincent; VAN WIJMEERSCH, Bart; Solaro, Claudio; Ramo-Tello, Cristina; Slee, Mark; Alroughani, Raed; Yamout, Bassem; Shaygannejad, Vahid; Spitaleri, Daniele; Luis Sanchez-Menoyo, Jose; Ampapa, Radek; Hodgkinson, Suzanne; Karabudak, Rana; Butler, Ernest; Vucic, Steve; Jokubaitis, Vilija; Spelman, Tim; Butzkueven, Helmut | Journal Contribution | A1 |
| 114 | 2019 | Therapeutic lag in relapsing multiple sclerosis | ROOSEN, Inge; Frascoli, F.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Izquierdo, G.; Eichau, S.; Patti, F.; Onofr, M.; Lugaresi, A.; Prat, A.; Girard, M.; Duquette, P.; Ozakbas, S.; Grammond, P.; Sola, P.; Ferraro, D.; Bergamaschi, R.; Boz, C.; Cartechini, E.; Sa, M. J.; Terzi, M.; Alroughani, R.; Grand'Maison, F.; Granella, F.; Iuliano, G.; Hupperts, R.; Lechner-Scott, J.; Spitaleri, D.; Van Pesch, V.; Soysal, A.; Prevost, J.; Aguera-Morales, E.; Olascoaga, J.; Turkoglu, R.; Sidhom, Y.; Gouider, R.; VAN WIJMEERSCH, Bart; Butzkueven, H.; Malpas, C.; Kalincik, T. | Journal Contribution | M |
| 115 | 2019 | Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) | Pelletier, Daniel; Arnold, Douglas L.; Boyko, Alexey N.; Comi, Giancarlo; Hartung, Hans-Peter; Havrdova, Eva Kubala; Inshasi, Jihad Said; McCombe, Pamela; Nakamura, Kunio; Oreja-Guevara, Celia; Pozzilli, Carlo; Selmaj, Krzysztof W.; Scott, Thomas F.; Chung, Luke; Daizadeh, Nadia; Afsar, Salman; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 116 | 2019 | Effectiveness and safety of Tetrahydrocannabinol - Cannabidiol Oromucosal spray in Belgian patients with multiple sclerosis spasticity: a retrospective data collection | POPESCU, Veronica; Vos, C.; van Dael, V.; Raeymaekers, G.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 117 | 2018 | Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I) | Broadley, S.; Wiendl, Heinz; Fernandez, O.; Freedman, M. S.; Izquierdo, G.; Lycke, J.; Pozzilli, C.; Sharrack, B.; Singer, B. A.; Steingo, B.; Vermersch, P.; Wray, S.; VAN WIJMEERSCH, Bart; Ziemssen, T.; Margolin, D. H.; Thangavelu, K.; Boster, A. | Journal Contribution | M |
| 118 | 2018 | No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; JACOBS, Andre; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 119 | 2018 | Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done! | PEETERS, Liesbet; van Munster, Caspar E.; VAN WIJMEERSCH, Bart; BRUYNDONCKX, Robin; LAMERS, Ilse; HELLINGS, Niels; POPESCU, Veronica; Thalheim, Christoph; FEYS, Peter | Journal Contribution | A1 |
| 120 | 2018 | Walking endurance and perceived symptom severity after a single maximal exercise test in persons with mild disability because of multiple sclerosis. | MOUMDJIAN, Lousin; GERVASONI, Elisa; VAN HALEWYCK, Florian; OP 'T EIJNDE, Bert; WENS, Inez; VAN GEEL, Fanny; VAN WIJMEERSCH, Bart; FEYS, Peter; VAN ASCH, Paul | Journal Contribution | A1 |
Loading...
5
0
5
0
false